Blue Flower

Aram Mangasarian, PhD

Chief Executive Officer

Aram Mangasarian was appointed CEO of NOXXON in July 2015. He has transformed NOXXON into a lean, publicly quoted company focused on targeting the tumor microenvironment to improve the treatment of solid tumors. Aram brings over twenty years experience in the biotechnology industry to NOXXON.

Prior to joining NOXXON in May 2010 as Chief Business Officer, Aram served as Vice-President Business Development for Novexel from October 2005 to March 2010. In this capacity he concluded a €150 million licensing agreement including a €75 million upfront payment with Forest Laboratories (NYSE:FRX) for North American rights to a beta-lactamase inhibitor now known as avibactam. Aram was a member of the management team that negotiated the acquisition of Novexel by AstraZeneca (NYSE:AZN) in March 2010 for up to $505 million.

From May 2000 to October 2005, Aram served in a variety of roles at ExonHit Therapeutics (now Diaxonhit, Euronext:ALEHT), eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the $30 million strategic alliance with Allergan.

Aram is a non-executive member of the board of directors of Isofol Medical AB, based in Gothenburg, Sweden, since June 2020.

Aram received a B.S. from the University of Wisconsin-Madison in biochemistry, molecular biology and English literature, a PhD in Biology from the University of California-San Diego for research carried out at the Salk Institute and an MBA from INSEAD.

Jarl Ulf Jungnelius, MD, PhD

Senior Medical Advisor

Jarl Ulf Jungnelius, MD, PhD joined NOXXON as Chief Medical Officer in February 2017 and remains a fundamental part of NOXXON’s top management as Senior Medical Advisor from May 2020. He is an oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations.

Jarl Ulf is CEO of Isofol Medical AB. He is also Supervisory Board director of Biovica International AB and Monocl AB and has been a director at Oncopeptides AB since April 2011.
Jarl Ulf held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta® and Revlimid®. He worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that post Jarl Ulf held leadership positions at Takeda, Pfizer, Eli Lilly & Company and VAXIMM, where he was responsible for clinical development of oncology programs as well as being involved in business development.

He received both a Bachelor of Science degree and his MD from the Karolinska Institute in Stockholm Sweden.